These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9333573)

  • 1. Efficacy of a three-component acellular pertussis vaccine (DTaP) in early childhood after household exposure to "typical" (WHO-defined) pertussis.
    Schmitt HJ
    Dev Biol Stand; 1997; 89():67-9. PubMed ID: 9333573
    [No Abstract]   [Full Text] [Related]  

  • 2. Case-control study to evaluate the efficacy of the BIKEN acellular pertussis vaccine combined with diphtheria and tetanus toxoids (DTaP) in infants.
    Beloradsky BH
    Dev Biol Stand; 1997; 89():70-3. PubMed ID: 9333574
    [No Abstract]   [Full Text] [Related]  

  • 3. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine.
    Stehr K; Cherry JD
    Dev Biol Stand; 1997; 89():58-62. PubMed ID: 9333571
    [No Abstract]   [Full Text] [Related]  

  • 5. Absolute efficacy of acellular pertussis vaccines in household settings.
    Storsaeter J; Gustafsson L
    Dev Biol Stand; 1997; 89():153-9. PubMed ID: 9272345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection.
    Heininger U; Stehr K; Christenson P; Cherry JD
    Clin Infect Dis; 1999 Mar; 28(3):602-4. PubMed ID: 10194085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy trial of acellular pertussis vaccines; trial I.
    Olin P
    Dev Biol Stand; 1997; 89():52-4. PubMed ID: 9333569
    [No Abstract]   [Full Text] [Related]  

  • 8. The Gothenburg pertussis vaccine study.
    Trollfors B; Taranger J
    Dev Biol Stand; 1997; 89():49-51. PubMed ID: 9333568
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative Efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group.
    Heininger U; Cherry JD; Stehr K; Schmitt-Grohé S; Uberall M; Laussucq S; Eckhardt T; Meyer M; Gornbein J
    Pediatrics; 1998 Sep; 102(3 Pt 1):546-53. PubMed ID: 9738175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sénégal pertussis trial.
    Simondon F
    Dev Biol Stand; 1997; 89():63-6. PubMed ID: 9333572
    [No Abstract]   [Full Text] [Related]  

  • 11. The effectiveness of whole-cell pertussis vaccines.
    Plotkin SA
    Dev Biol Stand; 1997; 89():171-4. PubMed ID: 9272348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pertussis vaccine trials. Trial synopses.
    Dev Biol Stand; 1997; 89():37-47. PubMed ID: 9333567
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety of acellular pertussis vaccine: follow-up studies.
    Chen RT
    Dev Biol Stand; 1997; 89():373-5. PubMed ID: 9272374
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
    Zepp F; Knuf M; Habermehl P; Mannhardt-Laakmann W; Howe B; Friedland LR
    J Pediatr; 2006 Nov; 149(5):603-610. PubMed ID: 17095328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants.
    Tapiainen T; Cherry JD; Heininger U
    Vaccine; 2005 Oct; 23(43):5106-12. PubMed ID: 16023771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of pertussis vaccine efficacy in the presence of covariates in three randomized trials.
    Blackwelder WC; VanRaden MJ; Deloria MA
    Dev Biol Stand; 1997; 89():161-6. PubMed ID: 9272346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules.
    Pichichero ME; Casey JR; Francis AB; Marsocci SM; Murphy M; Hoeger W; Cleary C
    Clin Pediatr (Phila); 2006 Sep; 45(7):613-20. PubMed ID: 16928838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus- inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections.
    Schmitt HJ; Knuf M; Ortiz E; Sänger R; Uwamwezi MC; Kaufhold A
    J Pediatr; 2000 Sep; 137(3):304-12. PubMed ID: 10969252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of different study designs for the evaluation of acellular pertussis vaccines.
    Fine PE
    Dev Biol Stand; 1997; 89():123-33. PubMed ID: 9272342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.